A review on B-type natriuretic peptide monitoring: assays and biosensors

Abstract

Since its discovery in 1988, B-type natriuretic peptide (BNP) has been recognized as a powerful cardiovascular biomarker for a number of disease states, specifically heart failure. Concurrent with such a discovery, much effort has been allocated to the precise monitoring of physiological BNP levels. Thus, it can be used to guide the therapy of heart failure and determine the patient’s stage of disease. Thus, we discuss in this article BNP as a potent biomarker. Subsequently, we will review the progress of biosensing devices as they could be applied to monitor BNP levels as assays, benchtop biosensors and implantable biosensors. The analytical characteristics of commercially available BNP assays are presented. Still emerging as a field, we define four obstacles that present opportunity for the future development of implantable biosensor: foreign body response, sensor renewability, sensitivity and selectivity.

Impact of B-Type Natriuretic Peptide Level on Risk Stratification of Thromboembolism and Death in Patients With Nonvalvular Atrial Fibrillation ― The Hokuriku-Plus AF Registry ―

“…B-type natriuretic peptide (BNP) has emerged as a powerful diagnostic tool for detecting acute HF and LV systolic and/or diastolic dysfunction. 8,9 In previous retrospective studies, a high BNP level was associated with left atrial appendage (LAA) thrombi, 10 and A trial fibrillation (AF) is the most common sustained arrhythmia. AF occurs together with many clinical risk factors and the development of AF is also influenced by genetic background.…”

Dynamic Changes in Circulating Plasma B-type Natriuretic peptide levels and its Influencing Factors in Patients with Hemorrhagic Fever with Renal Syndrome

“…BNP clearance is generally achieved by two routes, the most common one is binding to neutrophilic peptide chain endonuclease (NEP) on the membrane surface. In addition, BNP enters lysosomes through intracellular phagocytosis mediated by the receptor NPRC and then is degraded (27). Previous studies have suggested that BNP concentrations are strongly correlated with residual renal function (28,29), but several subsequent studies have reported that BNP only has a 21-22% or lower dependence on renal function for its clearance (30)(31)(32).…”

B-Type Natriuretic Peptide as a Significant Brain Biomarker for Stroke Triaging Using a Bedside Point-of-Care Monitoring Biosensor

“…BNP is a well-known diagnostic and prognostic biomarker in congestive HF [ 182 ]. Over the past decades, several commercial measurement devices for BNP detection in HF were developed ( Table 2 ) [ 183 ]. In the literature, there are earlier studies that showed the measurement of BNP in three commercial assays: TRIAGE (fully automated immunoassay), IRMA (non-competitive immune-radiometric assay), and RIA (competitive immune-radiometric assay).…”